Company intelligence / Profile preview

NeRRe Therapeutics

Stevenage, Hertfordshire, United Kingdomnerretherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase 2b study (VOLCANO-2) in patients with refractory or unexplained chronic cough, demonstrating that orvepitant 30 mg once daily resulted in rapid and sustained improvements in several clinically relevant patient reported outcome assessments of cough burden. Currently evaluating orvepitant for chronic cough in patients with IPF.

Therapeutic areas: Pulmonology
Modalities: Small molecules (neurokinin receptor antagonists)
Industry: Biotech

Drug pipeline

1 asset

orvepitant

Partnerships

GlaxoSmithKline (GSK) - original source of assets

Beyond the preview

Go deeper on NeRRe Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeRRe Therapeutics.

Explore the full profile